Treatment with the ROS1 inhibitor entrectinib yielded deep and durable responses in patients with ROS1 fusion-positive non–small cell lung cancer (ROS1+ NSCLC), including in those with brain metastases, according to a pooled analysis of three studies.
First-line therapy with the anti-programmed death ligand-1 (PD-L1) monoclonal antibody durvalumab improved overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) compared with platinum-based chemotherapy (CT), according to results from two analyses of the MYSTIC* trial presented at ELCC 2019.
Maintenance immunotherapy with the immune checkpoint inhibitors nivolumab and ipilimumab failed to improve overall survival (OS) in individuals with extensive-stage disease small-cell lung cancer (ED-SCLC), according to CheckMate 451* results presented at ELCC 2019.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
Multiple intralesional injections with purified protein derivative (PPD) leads to faster clearance of common warts compared with a single injection, although the latter is better tolerated, as shown in the results of an open‐label, superiority trial.
Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.